Claudia S. Cohn

Claudia S. Cohn

Auto-generated profile, based on publicly available information

Claudia S. Cohn

Department of Laboratory Medicine and Pathology University of Minnesota Medical School Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Open access
PDF file
CCClaudia S. Cohn
Claudia S. Cohn
Platelet refractoriness continues to be a problem for thrombocytopenic patients because the risk of a major spontaneous or life-threatening bleed significantly increases when platelet counts drop below 10 × 109/L. The majority of patients have nonimmune causes driving the refractoriness, such as bleeding, medications, or diffuse intravascular coagulation; however, this article is dedicated to the diagnosis and support of patients with immune-based platelet refractoriness. Antibodies to class I HLA molecules (A and B alleles) are responsible for most immune-based refractory cases, with antibodies to platelet antigens seen much less frequently. Patients may be supported with either crossmatch-compatible or HLA-matched/compatible platelet units. When trying to select HLA units it can be difficult to find a perfect “4 of 4” match for the patient’s class IA and IB alleles. In these cases, it is better to use the antibody specificity prediction method, which identifies compatible units that lack antigens recognized by the patient’s anti-HLA antibodies. For an algorithmic approach to the patient with platelet refractoriness, see Visual

16 April 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
CCClaudia S. Cohn
Claudia S. Cohn
JSJames Stubbs
James Stubbs
JSJoseph Schwartz
Joseph Schwartz
RFRichard Francis
Richard Francis
CGCheryl Goss
Cheryl Goss
WHW. Andrew Heaton
W. Andrew Heaton

16 August 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
LELise J. Estcourt
Lise J. Estcourt
CCClaudia S. Cohn
Claudia S. Cohn
MPMonica B. Pagano
Monica B. Pagano
CIClaire Iannizzi
Claire Iannizzi
NKNina Kreuzberger
Nina Kreuzberger
ATAaron A.R. Tobian
Aaron A.R. Tobian
The Association for the Advancement of Blood and Biotherapies developed clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma. This article describes the evidence and... Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for th...

21 July 2022 in Blood
Verified
Journal Article
Closed access
PDF file
ATAaron A. R. Tobian
Aaron A. R. Tobian
CCClaudia S. Cohn
Claudia S. Cohn
BSBeth H. Shaz
Beth H. Shaz
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were limited treatment options and no prophylactic therapies for those exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma is quick to implement, potentially provides benefits, and has a good safety profile. The therapeutic potential of COVID-19 convalescent plasma (CCP) is likely mediated by antibodies through direct viral neutralization and Fc-dependent functions such as a phagocytosis, complement activation, and antibody-dependent cellular cytotoxicity. In the United States, CCP became one of the most common treatments with more than a half million units transfused despite limited efficacy data. More than a dozen randomized trials now demonstrate that CCP does not provide benefit for those hospitalized with moderate to severe disease. However, similar to other passive antibody therapies, CCP is beneficial for early disease when provided to elderly outpatients within 72 hours after symptom onset. Only high-titer CCP should be transfused. CCP should also be considered for immunosuppressed patients with COVID-19. CCP collected in proximity, by time and location, to the patient may be more beneficial because of SARS-CoV-2 variants. Additional randomized trial data are still accruing and should be incorporated with other trial data to optimize CCP indications.

14 February 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
CCClaudia S. Cohn
Claudia S. Cohn
LELise Estcourt
Lise Estcourt
BGBrenda J. Grossman
Brenda J. Grossman
MPMonica B. Pagano
Monica B. Pagano
EAElizabeth S. Allen
Elizabeth S. Allen
ATAaron A. R. Tobian
Aaron A. R. Tobian
Background COVID‐19 convalescent plasma (CCP) has emerged as a potential treatment for COVID‐19. However, efficacy data and recommendations for its use are limited. Methods AABB commissioned a panel of experts to develop interim recommendations based on limited data to guide use of this scarce resource. The panel performed a literature review using the search terms “COVID‐19,” “SARS‐CoV‐2” and “convalescent plasma.” The interim recommendations reflect a consensus of expert opinion. Interim Recommendation 1 When making risk benefit decisions, one should consider the risk of CCP as comparable to standard (SARS‐CoV‐2 non‐immune) plasma. Interim Recommendation 2 CCP is optimally effective when transfused as close to symptom onset as possible. CCP is unlikely to provide benefit for patients with late‐stage disease or on mechanical ventilation. Interim Recommendation 3 The effectiveness of CCP is related to the antibody quantity within a unit; high‐titer CCP is superior to low‐titer CCP. A single high‐titer unit should be sufficient for most patients. Interim Recommendation 4 If group B or group AB CCP is unavailable, transfusion of group A or group O CCP with low anti‐A/B titer may be acceptable for group B and group AB patients. Interim Recommendation 5 Additional randomized controlled trial (RCT) data are needed to fully assess CCP efficacy and to identify which specific patient populations and unit characteristics might confer the greatest benefit. Conclusions These interim recommendations are based on the best‐available evidence at the time of writing. Additional data from on‐going RCTs will lead to clinical practice guidelines in the future.

1 January 2015 in Cancer Control
Verified
Journal Article
Open access
CCClaudia S. Cohn
Claudia S. Cohn
Patients receiving hematopoietic stem cell transplantation require extensive transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable complications may arise when the transplanted stem cells are incompatible with the native ABO type of the patient. Immediate and delayed hemolysis is often seen. A literature review was performed and the results from peer-reviewed papers that contained reproducible findings were integrated. A strong body of clinical evidence has developed around the common complications experienced with ABO-incompatible hematopoietic stem cell transplantation. These complications are discussed and the underlying pathophysiology is explained. General treatment options and guidelines are enumerated. ABO-incompatible hematopoietic stem cell transplantations are frequently performed. Immune-related hemolysis is a commonly encountered complication; therefore, health care professionals must recognize the signs of immune-mediated hemolysis and understand the various etiologies that may drive the process.